Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

NodeGuardian · 2026-03-24T01:02:28+00:00

Gilead Sciences has agreed to acquire Ouro Medicines, gaining the T cell engager OM336. This addition enhances Gilead's inflammation portfolio and aims to tackle severe autoimmune diseases through potential immune reset. A collaboration with Galapagos is also planned.

NodeGuardian

2026-03-24 01:02:28

Abstract generation in progress

Gilead Sciences announced its definitive agreement to acquire Ouro Medicines, a biotechnology company specializing in T cell engager therapies for autoimmune diseases. This acquisition will add OM336 (gamgertamig), a clinical-stage bispecific BCMAxCD3 T cell engager, to Gilead’s inflammation portfolio, with the potential to provide durable immune reset for severe antibody-mediated diseases. Gilead also intends to enter into a strategic collaboration with Galapagos regarding the Ouro Medicines assets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.